A Fefer
Overview
Explore the profile of A Fefer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
235
Citations
4001
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Golomb H, Ratain M, Fefer A, Thompson J, Portlock C, Ozer H, et al.
Leuk Lymphoma
. 2016 Jul;
5(5-6):335-40.
PMID: 27463343
This multicenter study reports on 49 patients with hairy cell leukemia (HCL) who were treated subcutaneously with alfa-2b interferon (Intron A, Schering Corporation, Kenilworth, N.J.), three times a week at...
2.
Golomb H, Fefer A, Golde D, Ozer H, Portlock C, Silber R, et al.
Leuk Lymphoma
. 2016 Jul;
4(2):99-102.
PMID: 27462938
One hundred ninety-five patients were entered into a multi-institutional study of interferon alfa 2b from 1983-1986; follow-up was completed through June 1989. A complete remission was documented in 7 patients,...
3.
4.
Deeg H, Shulman H, Anderson J, Bryant E, Gooley T, Slattery J, et al.
Blood
. 2000 Feb;
95(4):1188-94.
PMID: 10666189
We carried out bone marrow transplantation (BMT) in 50 patients with myelodysplastic syndrome (MDS) who were 55.3 to 66.2 years of age (median, 58.8 years). According to the criteria of...
5.
Gold P, Thompson J, Markowitz D, Neumann S, Fefer A
Cancer J Sci Am
. 1998 Feb;
3 Suppl 1:S85-91.
PMID: 9457401
Purpose: This article undertakes to define the response rate, long-term survival, and toxicity in patients with metastatic renal cell carcinoma (MRCC) treated with high-dose continuous intravenous infusion (CIV) recombinant interleukin-2...
6.
Fefer A, Robinson N, Benyunes M, Bensinger W, Press O, Thompson J, et al.
Cancer J Sci Am
. 1998 Feb;
3 Suppl 1:S48-53.
PMID: 9457394
Purpose: Autologous or allogeneic bone marrow transplantation (BMT) or stem cell transplantation (SCT) for advanced hematologic malignancies is associated with a high relapse rate. It has been postulated that recombinant...
7.
8.
Thompson J, Gold P, Markowitz D, Byrd D, Lindgren C, Fefer A
Cancer J Sci Am
. 1998 Feb;
3 Suppl 1:S29-34.
PMID: 9457390
Purpose: Aggressive inpatient chemoimmunotherapy protocols for metastatic melanoma have yielded encouraging response rates but have required lengthy hospitalizations. To reduce or eliminate the need for hospitalization, we have developed an...
9.
Lindgren C, Thompson J, Robinson N, Keeler T, Gold P, Fefer A
Bone Marrow Transplant
. 1997 May;
19(9):867-73.
PMID: 9156259
Interleukin-12 (IL-12) has been reported to enhance the cytolytic activity of NK and activated T cells and to induce low levels of lymphokine-activated killer (LAK) activity in normal human lymphocytes....
10.
Robinson N, Benyunes M, Thompson J, York A, Petersdorf S, Press O, et al.
Bone Marrow Transplant
. 1997 Mar;
19(5):435-42.
PMID: 9052908
The success of autologous stem cell transplantation (ASCT) for hematologic malignancy is limited largely by a high relapse rate. It is postulated that IL-2 administered after ASCT may eliminate minimal...